SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)
SELLAS Life Sciences shares surged on heavy volume to $2.64 after the company presented updated Phase 2 data for SLS009 in relapsed/refractory AML at ASH 2025. The study showed a 46% overall response rate among 35 patients, with no dose-limiting toxicities reported. Final analysis of the Phase 3 REGAL trial for galinpepimut-S is expected by year-end.